Роль молекулярно-генетическвх маркеров в скрининге рака предстательной железы: обзор литературы

Автор: Северин С.Е., Сивков А.В., Кешишев Н.Г., Кузнецова Е.М., Шкабко О.В.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Организация урологической помощи

Статья в выпуске: 3, 2012 года.

Бесплатный доступ

Рак предстательной железы, диагностика, опухолевые маркеры, генетические маркеры, молекулярные маркеры

Короткий адрес: https://sciup.org/142188322

IDR: 142188322

Список литературы Роль молекулярно-генетическвх маркеров в скрининге рака предстательной железы: обзор литературы

Лопаткин Н.А., Максимов В.А., Ходырева Л.А., Давыдова Е.Н. Оптимизация ранней диагностики заболеваний предстательной железы в условиях мегаполиса.//Урология. 2009. №5. С. 50-54
Чиссов В.И., Русаков И.Г. Заболеваемость раком предстательной железы в Российской Федерации.//Экспериментальная и клиническая урология. 2011. №2-3. С. 6-7.
Аполихин О.И., Сивков А.В., Бешлиев Д.А., Солнцева Т.В., Комарова В.А. Анализ уронефрологи-ческой заболеваемости в РФ по данным официальной статистики.//Экспериментальная и клиническая урология. 2010. № 1. С. 4-12.
Чиссов В.И., Старинский В.В., Петрова Г.В.Злокачественные опухоли в России: статистика, научные достижения, проблемы.//Казанский медицинский журнал. 2004. № 4. С. 241.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.//N Engl J Med. 1987. Vol. 317, N 15. P. 909-916.
Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, Igel TC, Kidd DD. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen.//J Urol. 1990. Vol. 143, N 6. P 1146-1152.
Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.//N Engl J Med. 1991, Vol. 324, N 17. P 1156-1161
Yao SL, Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era//J Natl Cancer Inst. 2002. Vol. 94, N 13. P. 958-960.
Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, Hamdy F, Stephens P, Lane JA, Moore R, Donovan J. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.//Lancet Oncol. 2008. Vol. 9, N 5. P 445-452.
Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A. Screening and prostate-cancer mortality in a randomized European study.//N Engl J Med. 2009. Vol. 360, N 13. P. 1320-1328.
O'Shaughnessy M, Konety B, Warlick C. Prostate cancer screening: issues and controversies.//Minn Med. 2010. Vol. 93, N 8. P. 39-44.
Baylin SB, Herman JG, Graff JR, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia//Adv. Cancer Res. 1998. Vol. 72. P. 141-196.
Bird A. The essentials of DNA methylation//Cell. 1992. Vol. 70, N 1. P. 5-8.
Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers//Nat. Med. 1995. Vol. 1, N 7. P. 686-692.
Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma//Proc Natl Acad Sci USA. 1998. Vol. 95, N 12. P. 6870-6875.
Cooper CS, Foster CS. Concepts of epigenetics in prostate cancer development//Br J Cancer. 2009. Vol. 100, N 2. P. 240-245.
Schaid DJ, Chang BL. Description of the International Consortium For Prostate Cancer Genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13.//Prostate. 2005. Vol. 63, N 3. P. 276290.
Kopper L, Timar J. Genomics of prostate cancer: is there anything to "translate"?//Pathol Oncol Res. 2005. Vol. 11, N 4. P 197-203.
Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk.//Cancer Res. 1995. Vol. 55, N 18. P. 3973-5.
Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer.//Proc Natl Acad Sci USA. 1997. Vol. 94, N 7. P 3320-3.
Cheng I, Witte JS, Jacobsen SJ, Haque R, Quinn VP, Quesenberry CP, Caan BJ, Van Den Eeden SK. Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men's Health Study.//PLoS One. 2010. Vol. 5, N 1. P 8736.
Robbins C, Torres JB, Hooker S, Bonilla C, Hernandez W, Candreva A, Ahaghotu C, Kittles R, Carpten J.Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus.//Genome Res. 2007. Vol. 17, N 12. P 1717-1722.
Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Martignetti JA, Friedman SL. KLF6, a candidate tumor suppressor gene mutated in prostate cancer.//Science. 2001. Vol. 294, N 5551. P 2563-6.
Nelson WG, Yegnasubramanian S, Agoston AT, Bastian PJ, Lee BH, Nakayama M, De Marzo AM. Abnormal DNA methylation, epigenetics, and prostate cancer//Front. Biosci. 2007. Vol. 12. P. 4254-4266.
Dobosy JR, Roberts JL, Fu VX, Jarrard DF. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia//J Urol. 2007. Vol. 177, N 3. P. 822-831.
Li LC. Epigenetics of prostate cancer//Front. Biosci. 2007. Vol. 12. P. 3377-3397.
Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps//Nat Rev Genet. 2007. Vol. 8, N 4. P. 286-298.
Hoque MO, Kim MS, Ostrow KL, Liu J, Wisman GB, Park HL, Poeta ML, Jeronimo C, Henrique R, Lendvai A, Schuuring E, Begum S, Rosenbaum E, Ongenaert M, Yamashita K, Califano J, Westra W, van der Zee AG, Van Criekinge W, Sidransky D. Genome-wide promoter analysis uncovers portions of the cancer methylome//Cancer Res. 2008. Vol. 68, N 8. P. 2661-2670.
Ngan RK, Lau WH, Yip TT, Cho WC, Cheng WW, Lim CK, Wan KK, Chu E, Joab I, Grunewald V, Poon YF, Ho JH. Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy//Ann NY Acad Sci. 2001. Vol. 945. P. 73-79.
Henrique R, Costa VL, Cerveira N, Carvalho AL, Hoque MO, Ribeiro FR, Oliveira J, Teixeira MR, Sidransky D, Jeronimo C. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer//J Mol Med. 2006. Vol. 84, N 11. P. 911-918.
Henrique R, Jeronimo C, Hoque MO, Carvalho AL, Oliveira J, Teixeira MR, Lopes C, Sidransky D. Frequent 14-13-3 promoter methylation in benign and malignant prostate lesions//DNA Cell Biol. 2005. Vol. 24, N 4. P. 264-269.
Ellinger J, von Rucker A, Wernert N, Buttner R, Bastian PJ, Muller SC. Prostate cancer research. Biomarkers as promising options for optimized diagnosis and treatment.//Urologe A. 2008. Vol. 47, N 9. P. 1190-2.
Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG, Shariat SF.Epigenetics in prostate cancer: biologic and clinical relevance.//Eur Urol. 2011. Vol. 60, N 4. P. 753766.
Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, Costa VL, Pinto M, Oliveira J, Teixeira MR, Sidransky D, Jeronimo C. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients//Clin Cancer Res. 2007. Vol. 13, N 20. P. 6122-6129.
Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D. A quantitative promoter methylation profile of prostate cancer//Clin Cancer Res. 2004. Vol. 10, N 24. P. 8472-8478.
Nonn L, Ananthanarayanan V, Gann PH. Evidence for field cancerization of the prostate//Prostate. 2009. Vol. 69, N 13. P. 1470-1479.
Vener T, Derecho C, Baden J, Wang H, Rajpurohit Y, Skelton J, Mehrotra J, Varde S, Chowdary D, Stallings W, Leibovich B, Robin H, Pelzer A, Schafer G, Auprich M, Mannweiler S, Amersdorfer P, Mazumder A. Development of a multiplexed urine assay for prostate cancer diagnosis//Clin Chem. 2008. Vol. 54, N 5. P. 874-882.
Meyer HA, Ahrens-Fath I, Sommer A, Haendler B. Novel molecular aspects of prostate carcinogenesis.//Biomed Pharmacother. 2004. Vol. 58, N 1. P. 10-6.
Aitchison A, Warren A, Neal D, Rabbitts P. et al. RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues//Prostate. 2007. Vol. 67, N 6. P. 638-644.
Krop I, Player A, Tablante A, Taylor-Parker M, Lahti-Domenici J, Fukuoka J, Batra SK, Papadopoulos N, Richards WG, Sugarbaker DJ, Wright RL, Shim J, Stamey TA, Sellers WR, Loda M, Meyerson M, Hruban R, Jen J, Polyak K. Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types//Mol Cancer Res. 2004. Vol. 2, N 9. P. 489-494.
Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer//Oncogene. 2002. Vol. 21, N 44. P. 6835-6840.
Tozawa K, Akita H, Kawai N, Okamura T, Sasaki S, Hayashi Y, Kohri K.KAI1 expression can be a predictor of stage A prostate cancer progression.//Prostate Cancer Prostatic Dis. 2001. Vol. 4, N 3. P. 150-153.
Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, Choon A, Reznikoff CR, Bova GS, Friedl A, Jarrard DF. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer.//Cancer Res. 2000. Vol. 60, N 13. P. 3623-30.
Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X, De Marzo AM, Nelson WG. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation.//Eur Urol. 2004. Vol. 46, N 6. P. 698-708.
Harden SV, Sanderson H, Goodman SN, Partin AA, Walsh PC, Epstein JI, Sidransky D. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies.//J Natl Cancer Inst. 2003. Vol. 95, N 21. P. 1634-1637.
Florl AR, SteinhoffC, Muller M, Seifert HH, Hader C, Engers R, Ackermann R, Schulz WA. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation.//Br J Cancer. 2004. Vol. 91, N 5. P. 985-994.
Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.//J Clin Oncol. 2003. Vol. 21, N 14. P. 2673-8.
Luo JH. Gene expression alterations in human prostate cancer.//Drugs Today (Barc). 2002. Vol. 38, N 10. P. 713-719.
Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis.//Cancer Cell. 2004. Vol. 6, N 2. P. 185-95.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer//Science. 2005. Vol. 310, N 5748. P. 644-648.
Tomlins SA, Rubin MA, Chinnaiyan AM. Integrative biology of prostate cancer progression//Annu Rev Pathol. 2006. Vol. 1. P. 243-271.
Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion//Am J Surg Pathol. 2007. Vol. 31, N 6. P. 882-888.
Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS, Scardino P, Cuzick J, Cooper CS. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer//Oncogene. 2008. Vol. 27, N 3. P. 253-263.

Еще

Статья